Price (delayed)
$3.1
Market cap
$152.17M
P/E Ratio
6.46
Dividend/share
N/A
EPS
$0.48
Enterprise value
$171.28M
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights
There are no recent dividends present for PBYI.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.